此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients (RIMOSTROKE-2)

2026年11月16日 更新者:Sinfatin S.L

Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase (RIMOSTROKE-2)

The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.

Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.

研究概览

地位

尚未招聘

详细说明

Stroke is a major cause of disability worldwide. Many patients experience persistent functional limitations that can affect their independence in daily activities and quality of life, despite being involved in rehabilitation programs.

The endocannabinoid system, particularly the cannabinoid type 1 (CB1) receptor, is involved in the regulation of neuronal activity and motor function. Rimonabant is a selective CB1 receptor antagonist/inverse agonist that has demonstrated effects on corticospinal excitability and motor performance in previous preclinical and clinical research.

Based on this evidence, this study aims to investigate whether treatment with low-dose rimonabant can improve functional independence in post-stroke patients during the subacute phase. RIMOSTROKE-2 is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial, to evaluate efficacy and safety of rimonabant.

The primary objective is to evaluate the effect of rimonabant on functional independence, measured by the change in the total Barthel Index (BI) score. Secondary objectives include assessing motor function, walking ability, balance, fatigue, neurological status, cognitive function and health-related quality of life. The safety and tolerability of rimonabant will also be evaluated through adverse event monitoring, clinical examinations, laboratory tests, vital signs and electrocardiogram.

The treatment period will last 90 days, followed by a 45-day follow-up period. All participants will continue to receive standard medical care and rehabilitation.

研究类型

介入性

注册 (估计的)

80

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Albacete
      • Albacete、Albacete、西班牙、02006
        • Hospital Universitario de Albacete
        • 接触:
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • Institut Guttmann
        • 接触:
    • Córdoba
      • Córdoba、Córdoba、西班牙、14004
        • Jiménez Lucena S.L. (CLÍNICA I+TÚ)
        • 接触:
    • Madrid
      • Brunete、Madrid、西班牙、28690
        • Hospital Los Madroños
        • 接触:
      • Madrid、Madrid、西班牙、28046
      • Madrid、Madrid、西班牙、28040
        • Hospital Clínico San Carlos (HCSC)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age between 18 and 75 years.
  • Between 30 days and 3 months (30 - 90 days) since the stroke.
  • mRS score between 2 and 4.
  • BI score ≤ 70 at screening.
  • Capacity to provide informed consent.

Exclusion Criteria:

  • High suicide risk assessed by C-SSRS.
  • History of severe psychiatric disorders, major depression or prior suicide attempts.
  • Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort).
  • Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions.
  • BMI > 40 kg/m².
  • Pregnancy or breastfeeding.
  • Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines at least 45 days after the last dose of rimonabant -i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (CTFG, 2020).
  • Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease.
  • Known allergy to rimonabant or any of the excipients used.
  • Participation in another clinical trial within the month prior to enrolment.
  • Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Rimonabant 5 mg

Participants randomized to receive rimonabant 5 mg.

Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.

安慰剂比较:Placebo

Participants randomized to receive matching placebo.

Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Barthel Index (BI)
大体时间:Baseline and end of follow-up (day 135)

The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.

Baseline and end of follow-up (day 135)

次要结果测量

结果测量
措施说明
大体时间
Five-level EuroQol five-dimension questionnaire (EQ-5D-5L)
大体时间:Baseline and end of follow-up (day 135)

The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set.

Baseline and end of follow-up (day 135)
Adverse Events (AEs)
大体时间:Baseline and end of follow-up (day 135)

Number of participants experiencing at least one adverse event (AE). Adverse events will be recorded and assessed by severity, causality, and type.

Baseline and end of follow-up (day 135)
Serious Adverse Events (SAEs)
大体时间:Baseline and end of follow-up (day 135)

Number of participants experiencing at least one serious adverse event (SAE) during the study.

Baseline and end of follow-up (day 135)
Adverse Events of Special Interest (AESIs)
大体时间:Baseline and end of follow-up (day 135)

Number of participants experiencing at least one protocol-defined adverse event of special interest. Particular attention is given to psychiatric events and clinically relevant changes in mental status because of the known psychiatric risk profile of rimonabant.

Baseline and end of follow-up (day 135)
Beck Depression Inventory-II (BDI-II)
大体时间:Baseline and end of follow-up (day 135)

The Beck Depression Inventory-II (BDI-II) assesses depressive symptoms. Higher scores indicate greater depressive symptom severity. According to the protocol, a score ≥20 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
The Visual Analogue Scale for Pain (VAS-P)
大体时间:Baseline and end of follow-up (day 135)

Assesses the participant's subjective perception of pain intensity. Changes from baseline will be used to identify clinically significant changes in pain during treatment and follow-up.

Baseline and end of follow-up (day 135)
Spasticity Assessed by Modified Ashworth Scale (MAS)
大体时间:Baseline and end of follow-up (day 135)

The MAS assesses resistance to passive movement as a measure of muscle spasticity. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate category of 1+. Higher scores indicate greater spasticity.

Baseline and end of follow-up (day 135)
Number of Falls
大体时间:Baseline and end of follow-up (day 135)

Mean number of falls during the previous 30 days, based on weekly records in the participant diary and collected at each follow-up visit.

Baseline and end of follow-up (day 135)
Six-Minute Walk Test (6MWT)
大体时间:Baseline and end of follow-up (day 135)

The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.

Baseline and end of follow-up (day 135)
Ten-Meter Walk Test (10MWT)
大体时间:Baseline and end of follow-up (day 135)

The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second.

Baseline and end of follow-up (day 135)
Borg CR10 Scale
大体时间:Baseline and end of follow-up (day 135)

The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion.

Baseline and end of follow-up (day 135)
Fatigue Severity Scale (FSS)
大体时间:Baseline and end of follow-up (day 135)

The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity.

Baseline and end of follow-up (day 135)
Stroke Impact Scale (SIS 3.0)
大体时间:Baseline and end of follow-up (day 135)

The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations.

Baseline and end of follow-up (day 135)
Patient Global Impression of Change (PGIC)
大体时间:End of treatment (day 90) and End of follow-up (day 135)

The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change.

End of treatment (day 90) and End of follow-up (day 135)
Hospital Anxiety and Depression Scale-Anxiety (HADS-A)
大体时间:Baseline and end of follow-up (day 135)

The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) assesses anxiety symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
Hospital Anxiety and Depression Scale-Depression (HADS-D)
大体时间:Baseline and end of follow-up (day 135)

The depression subscale of the Hospital Anxiety and Depression Scale (HADS) assesses depresive symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
Timed Up and Go test (TUG)
大体时间:Baseline and end of follow-up (day 135)

The TUG assesses functional mobility and fall risk by measuring the time taken to stand up from a chair, walk 3 meters, turn around, return and sit down. Longer times indicate poorer functional mobility and a higher risk of falls.

Baseline and end of follow-up (day 135)
Berg Balance Scale (BBS)
大体时间:Baseline and end of follow-up (day 135)

The BBS assesses static and dynamic balance through 14 functional tasks, providing a quantitative measure of postural control and fall risk. Higher scores indicate better balance and a lower risk of falls.

Baseline and end of follow-up (day 135)
Fugl-Meyer Assessment - Upper Extremities (FMA-UE)
大体时间:Baseline and end of follow-up (day 135)

The FMA-UE assesses upper limb motor function after stroke, evaluating movement control, coordination and reflex activity. Higher scores indicate better motor function and less severe upper limb impairment.

Baseline and end of follow-up (day 135)
National Institutes of Health Stroke Scale (NIHSS)
大体时间:Baseline and end of follow-up (day 135)

The NIHSS assesses the severity of neurological deficits after stroke by evaluating consciousness, language, motor, sensory and visual functions. Scores range from 0 to 42, with higher scores indicating greater neurological impairment and more severe stroke symptoms.

Baseline and end of follow-up (day 135)
Modified Rankin Scale (mRS)
大体时间:Baseline and end of follow-up (day 135)

The mRS assesses the degree of global disability and dependence in activities of daily living (ADL) following a neurological event. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability and dependence.

Baseline and end of follow-up (day 135)
Montreal Cognitive Assessment (MoCA)
大体时间:Baseline and end of follow-up (day 135)

The MoCA assesses global cognitive function through the evaluation of attention, memory, executive functions, language, visuospatial abilities and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

Baseline and end of follow-up (day 135)
Swallowing Disturbance Questionnaire (SDQ)
大体时间:Baseline and end of follow-up (day 135)

The SDQ assesses the presence and severity of swallowing disorders through a self-reported questionnaire, identifying symptoms associated with dysphagia. Higher scores indicate more severe swallowing difficulties and a greater likelihood of dysphagia.

Baseline and end of follow-up (day 135)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月30日

初级完成 (估计的)

2028年1月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • RIMOSTROKE-2
  • 2025 (美国 NIH 拨款/合同)
  • 2025-521689-86-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅